300 related articles for article (PubMed ID: 25258407)
1. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function.
Bajaj JS; Cox IJ; Betrapally NS; Heuman DM; Schubert ML; Ratneswaran M; Hylemon PB; White MB; Daita K; Noble NA; Sikaroodi M; Williams R; Crossey MM; Taylor-Robinson SD; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2014 Nov; 307(10):G951-7. PubMed ID: 25258407
[TBL] [Abstract][Full Text] [Related]
2. Proton Pump Inhibitor Initiation and Withdrawal affects Gut Microbiota and Readmission Risk in Cirrhosis.
Bajaj JS; Acharya C; Fagan A; White MB; Gavis E; Heuman DM; Hylemon PB; Fuchs M; Puri P; Schubert ML; Sanyal AJ; Sterling RK; Stravitz TR; Siddiqui MS; Luketic V; Lee H; Sikaroodi M; Gillevet PM
Am J Gastroenterol; 2018 Aug; 113(8):1177-1186. PubMed ID: 29872220
[TBL] [Abstract][Full Text] [Related]
3. Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.
Bajaj JS; Betrapally NS; Hylemon PB; Heuman DM; Daita K; White MB; Unser A; Thacker LR; Sanyal AJ; Kang DJ; Sikaroodi M; Gillevet PM
Hepatology; 2015 Oct; 62(4):1260-71. PubMed ID: 25820757
[TBL] [Abstract][Full Text] [Related]
4. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.
Tomkovich S; Lesniak NA; Li Y; Bishop L; Fitzgerald MJ; Schloss PD
mSphere; 2019 Nov; 4(6):. PubMed ID: 31748246
[TBL] [Abstract][Full Text] [Related]
5. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability.
van Vlerken LG; Huisman EJ; van Hoek B; Renooij W; de Rooij FW; Siersema PD; van Erpecum KJ
Eur J Clin Invest; 2012 Jul; 42(7):760-7. PubMed ID: 22288900
[TBL] [Abstract][Full Text] [Related]
6. Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.
Bajaj JS; Thacker LR; Fagan A; White MB; Gavis EA; Hylemon PB; Brown R; Acharya C; Heuman DM; Fuchs M; Dalmet S; Sikaroodi M; Gillevet PM
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515036
[TBL] [Abstract][Full Text] [Related]
7. Stool microbiota show greater linkages with plasma metabolites compared to salivary microbiota in a multinational cirrhosis cohort.
Cox IJ; Peña Rodríguez M; Fagan A; Rojas-Lara MV; Le Guennec A; Rodriguez-Alvarez F; McGeorge S; Escalona-Nandez I; Torre A; Bajaj JS
Liver Int; 2022 Oct; 42(10):2274-2282. PubMed ID: 35635305
[TBL] [Abstract][Full Text] [Related]
8. Altered profile of human gut microbiome is associated with cirrhosis and its complications.
Bajaj JS; Heuman DM; Hylemon PB; Sanyal AJ; White MB; Monteith P; Noble NA; Unser AB; Daita K; Fisher AR; Sikaroodi M; Gillevet PM
J Hepatol; 2014 May; 60(5):940-7. PubMed ID: 24374295
[TBL] [Abstract][Full Text] [Related]
9. Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.
Saboo K; Petrakov NV; Shamsaddini A; Fagan A; Gavis EA; Sikaroodi M; McGeorge S; Gillevet PM; Iyer RK; Bajaj JS
J Hepatol; 2022 Mar; 76(3):600-607. PubMed ID: 34793867
[TBL] [Abstract][Full Text] [Related]
10. The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients.
Wellhöner F; Döscher N; Tergast TL; Vital M; Plumeier I; Kahl S; Potthoff A; Manns MP; Maasoumy B; Wedemeyer H; Cornberg M; Pieper DH; Heidrich B
Scand J Gastroenterol; 2019 Aug; 54(8):1033-1041. PubMed ID: 31361979
[No Abstract] [Full Text] [Related]
11. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial.
Freedberg DE; Toussaint NC; Chen SP; Ratner AJ; Whittier S; Wang TC; Wang HH; Abrams JA
Gastroenterology; 2015 Oct; 149(4):883-5.e9. PubMed ID: 26164495
[TBL] [Abstract][Full Text] [Related]
12. Oral microbiome alterations of healthy volunteers with proton pump inhibitor.
Mishiro T; Oka K; Kuroki Y; Takahashi M; Tatsumi K; Saitoh T; Tobita H; Ishimura N; Sato S; Ishihara S; Sekine J; Wada K; Kinoshita Y
J Gastroenterol Hepatol; 2018 May; 33(5):1059-1066. PubMed ID: 29105152
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis.
Labenz C; Kostev K; Galle PR; Wörns MA; Labenz J; Tanislav C; Adarkwah CC
Medicine (Baltimore); 2020 Dec; 99(50):e23436. PubMed ID: 33327272
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis.
Horvath A; Rainer F; Bashir M; Leber B; Schmerboeck B; Klymiuk I; Groselj-Strele A; Durdevic M; Freedberg DE; Abrams JA; Fickert P; Stiegler P; Stadlbauer V
Sci Rep; 2019 Aug; 9(1):12000. PubMed ID: 31427714
[TBL] [Abstract][Full Text] [Related]
15. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.
Bajaj JS; Hylemon PB; Ridlon JM; Heuman DM; Daita K; White MB; Monteith P; Noble NA; Sikaroodi M; Gillevet PM
Am J Physiol Gastrointest Liver Physiol; 2012 Sep; 303(6):G675-85. PubMed ID: 22821944
[TBL] [Abstract][Full Text] [Related]
16. Long-term Proton Pump Inhibitor Administration Caused Physiological and Microbiota Changes in Rats.
Yang YSH; Chang HW; Lin IH; Chien LN; Wu MJ; Liu YR; Chu PG; Xie G; Dong F; Jia W; Chang VHS; Yen Y
Sci Rep; 2020 Jan; 10(1):866. PubMed ID: 31964941
[TBL] [Abstract][Full Text] [Related]
17. Low gut microbiota diversity and dietary magnesium intake are associated with the development of PPI-induced hypomagnesemia.
Gommers LMM; Ederveen THA; van der Wijst J; Overmars-Bos C; Kortman GAM; Boekhorst J; Bindels RJM; de Baaij JHF; Hoenderop JGJ
FASEB J; 2019 Oct; 33(10):11235-11246. PubMed ID: 31299175
[TBL] [Abstract][Full Text] [Related]
18. Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus.
Bajaj JS; Betrapally NS; Hylemon PB; Thacker LR; Daita K; Kang DJ; White MB; Unser AB; Fagan A; Gavis EA; Sikaroodi M; Dalmet S; Heuman DM; Gillevet PM
Sci Rep; 2015 Dec; 5():18559. PubMed ID: 26692421
[TBL] [Abstract][Full Text] [Related]
19. Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis.
Bajaj JS; Shamsaddini A; Acharya C; Fagan A; Sikaroodi M; Gavis E; McGeorge S; Khoruts A; Fuchs M; Sterling RK; Lee H; Gillevet PM
Gut Microbes; 2021; 13(1):1993584. PubMed ID: 34743650
[TBL] [Abstract][Full Text] [Related]
20. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
